Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA1 | P30542 | 3/20 | 0.34 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | NSD2 | O96028 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22001038 | 0.78 | ADORA2A (0.41) | ADORA1ADORA2AALDH1A1KDM4ENSD2 | |
| SCHEMBL31313980 | 0.73 | FOS (0.33) | ADORA1ADORA2AALDH1A1ADORA3 | |
| SCHEMBL21676523 | 0.71 | ADORA1 (0.34) | ADORA1ADORA2AALDH1A1KDM4ENSD2 | |
| SCHEMBL15980404 | 0.71 | MAPT (0.36) | ALDH1A1KDM4ENSD2MAPT | |
| SCHEMBL15980358 | 0.69 | CCR1 (0.47) | ADORA1ADORA2AALDH1A1KDM4ENSD2 | |
| SCHEMBL15833604 | 0.68 | MAPT (0.41) | ADORA1ADORA2AALDH1A1KDM4ENSD2 | |
| SCHEMBL24121909 | 0.67 | PDK2 (0.32) | — | |
| SCHEMBL26723705 | 0.67 | ADORA2A (0.46) | ADORA1ADORA2AALDH1A1ADORA3 | |
| SCHEMBL16320778 | 0.64 | ALDH1A1 (0.41) | ALDH1A1 | |
| SCHEMBL22001420 | 0.64 | PAK4 (0.46) | ADORA1ADORA2AALDH1A1KDM4ENSD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250051319-A1 | COMPOUNDS AND USE THEREOF AS HDAC6 INHIBITORS | AUGUSTINE THERAPEUTICS (BE) | 2025-02-13 | — | — | US | claimed |
| US-12421222-B2 | Substituted quinazolines as HDAC6 inhibitors | AUGUSTINE THERAPEUTICS (BE) | 2025-09-23 | — | — | US | disclosed |
| US-20250145604-A1 | COMPOUNDS AND USE THEREOF AS HDAC6 INHIBITORS | AUGUSTINE THERAPEUTICS (BE) | 2025-05-08 | — | — | US | disclosed |
| US-20250051319-A1 | COMPOUNDS AND USE THEREOF AS HDAC6 INHIBITORS | AUGUSTINE THERAPEUTICS (BE) | 2025-02-13 | — | — | US | disclosed |
| US-9133129-B2 | Bicyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-09-15 | — | — | US | disclosed |
| US-9133129-B2 | Bicyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-09-15 | — | — | US | disclosed |
| US-20140243310-A1 | BICYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2014-08-28 | — | — | US | disclosed |
| US-20140243310-A1 | BICYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2014-08-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250051319-A1 | COMPOUNDS AND USE THEREOF AS HDAC6 INHIBITORS | HDAC6, HDAC9, HDAC1 | ADORA1 4645/4885ADORA2A 4698/4885ALDH1A1 608/4885 |
| US-20250145604-A1 | COMPOUNDS AND USE THEREOF AS HDAC6 INHIBITORS | HDAC6, HDAC9, HDAC1 | ADORA1 4645/4885ADORA2A 4698/4885ALDH1A1 608/4885 |
| US-20140243310-A1 | BICYCLIC COMPOUND | BICRA, NR3C2, CYP11B2 | ADORA1 2097/4885ADORA2A 2471/4885ALDH1A1 450/4885 |
| US-12421222-B2 | Substituted quinazolines as HDAC6 inhibitors | HDAC6, HDAC9, HDAC1 | ADORA1 4485/4885ADORA2A 4599/4885ALDH1A1 850/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.